We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+4.68%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$882M
AUM Growth
+$286M
(+48%)
Cap. Flow
+$377M
Cap. Flow
% of AUM
42.79%
Top 10 Holdings %
Top 10 Hldgs %
91.23%
Holding
26
New
6
Increased
1
Reduced
2
Closed
1
Avg Time Held
6.2
quarters
Top 10 Avg Time Held
5.5
quarters
Top 20 Avg Time Held
5.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcutis Biotherapeutics
ARQT
|
+$283M |
| 2 |
Passage Bio
PASG
|
+$78.3M |
| 3 |
Adverum Biotechnologies
ADVM
|
+$11.8M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$9.3M |
| 5 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$9.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Collegium Pharmaceutical
COLL
|
+$19.5M |
| 2 |
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
|
+$1.35M |
| 3 |
Kezar Life Sciences
KZR
|
+$363K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Arcutis Biotherapeutics
ARQT
$3.28B
| $314M | 35.62% |
+10,542,790
| New | +$283M |
2020 Q1
0 quarters
|
|
2
Phathom Pharmaceuticals
PHAT
$566M
| $188M | 21.33% |
7,284,269
| – | – |
2019 Q4
1 quarter
|
|
|
3
Passage Bio
PASG
$11.7M
| $78.9M | 8.95% |
+250,461
| New | +$78.3M |
2020 Q1
0 quarters
|
|
4
Iovance Biotherapeutics
IOVA
$6.57B
| $52.4M | 5.94% |
1,750,665
| – | – |
2016 Q2
15 quarters
|
|
5
Mirum Pharmaceuticals
MIRM
$5.17B
| $49.9M | 5.66% |
3,566,912
| – | – |
2019 Q3
2 quarters
|
|
6
Krystal Biotech
KRYS
$9.51B
| $38.7M | 4.39% |
895,000
| – | – |
2018 Q3
6 quarters
|
|
7
AnaptysBio
ANAB
$1.36B
| $32.7M | 3.71% |
2,316,447
| – | – |
2017 Q1
12 quarters
|
|
8
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $21.8M | 2.47% |
2,182,789
| – | – |
2019 Q2
3 quarters
|
|
|
9
Collegium Pharmaceutical
COLL
$701M
| $15.4M | 1.75% |
943,666
-943,666
| -50% | -$19.5M |
2015 Q4
17 quarters
|
|
|
10
DELISTED
Adverum Biotechnologies
ADVM
| $12.5M | 1.42% |
127,833
+100,999
| +376% | +$11.8M |
2019 Q4
1 quarter
|
|
11
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $12M | 1.36% |
2,061,758
| – | – |
2018 Q3
6 quarters
|
|
|
12
Syndax Pharmaceuticals
SNDX
$1.25B
| $10.9M | 1.23% |
+990,711
| New | +$9.3M |
2020 Q1
0 quarters
|
|
|
TRIL
13
DELISTED
Trillium Therapeutics Inc.
TRIL
| $9.55M | 1.08% |
+2,443,809
| New | +$9.24M |
2020 Q1
0 quarters
|
|
14
DELISTED
Alpine Immune Sciences Inc
ALPN
| $7.41M | 0.84% |
2,571,450
| – | – |
2017 Q3
10 quarters
|
|
15
Tempest Therapeutics
TPST
$11.5M
| $7.37M | 0.84% |
7,162
| – | – |
2018 Q4
5 quarters
|
|
|
APTX
16
DELISTED
Aptinyx Inc. Common Stock
APTX
| $6.89M | 0.78% |
3,190,079
| – | – |
2018 Q2
7 quarters
|
|
17
DELISTED
Iterum Therapeutics
ITRM
| $4.17M | 0.47% |
102,554
| – | – |
2018 Q2
7 quarters
|
|
18
DELISTED
Cidara Therapeutics
CDTX
| $3.25M | 0.37% |
65,613
| – | – |
2015 Q4
17 quarters
|
|
|
ALNA
19
DELISTED
Allena Pharmaceuticals
ALNA
| $3.21M | 0.36% |
3,330,373
| – | – |
2017 Q4
9 quarters
|
|
20
Rocket Pharmaceuticals
RCKT
$252M
| $2.93M | 0.33% |
+210,000
| New | +$4.16M |
2020 Q1
0 quarters
|
|
|
ETTX
21
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $2.77M | 0.31% |
1,049,953
-300,000
| -22% | -$1.35M |
2018 Q3
6 quarters
|
|
|
NBRV
22
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $2.45M | 0.28% |
17,026
| – | – |
2018 Q3
6 quarters
|
|
23
vTv Therapeutics
VTVT
$112M
| $2.03M | 0.23% |
+26,550
| New | +$2.55M |
2020 Q1
0 quarters
|
|
|
SRRA
24
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.99M | 0.23% |
202,803
| – | – |
2015 Q4
17 quarters
|
|
|
BLCM
25
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $495K | 0.06% |
105,144
| – | – |
2018 Q2
7 quarters
|
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q1 2020 Portfolio in Review
As of Q1 2020, Frazier Management held 26 positions worth $882M, up 48% from $596M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Frazier Management deployed $377M of net new capital in Q1 2020, opening 6 new positions and adding to 1 existing holding. Its largest new stake was Arcutis Biotherapeutics: 10,542,790 shares worth $314M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Collegium Pharmaceutical, an estimated $19.5M trimmed.
- Frazier Management's largest Q1 2020 buy was Arcutis Biotherapeutics: 10,542,790 shares worth $314M.
- Frazier Management added most to Adverum Biotechnologies in Q1 2020, an estimated $11.8M increase.
- Frazier Management's biggest Q1 2020 reduction was Collegium Pharmaceutical, cutting an estimated $19.5M.
- Frazier Management fully exited Kezar Life Sciences in Q1 2020, selling an estimated $363K.
- Frazier Management's ten largest holdings make up 91% of its $882M portfolio in Q1 2020.
- Frazier Management opened 6 new positions and closed 1 in Q1 2020.
- Frazier Management's portfolio value rose 48% quarter-over-quarter to $882M.
Based on Frazier Management's 13F filing for Q1 2020, filed 13 May 2020.